Antonio Migliarese assumes interim President roleDr. Melissa Palmer appointed interim Chief Medical OfficerDr. Salah Kivlighn joins CytoDyn as clinical and strategic advisor VANCOUVER, Washington,. | June 11, 2023
Salah Kivlighn and HepaTx are trailblazers in the regenerative medicine technologies space einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
HepaTx appoints Salah Kivlighn as new CEO
News provided by
Share this article
Share this article
PALO ALTO, Calif., April 15, 2021 /PRNewswire/ HepaTx Corporation, a preclinical stage company developing cell therapies for the treatment of liver disease, is pleased to announce the appointment of Salah Kivlighn, PhD as Chief Executive Office. An experienced business leader, Dr. Kivlighn will succeed Co-founder Eric Schuur, PhD and assume responsibilities on April 15
th, 2021.
Dr. Kivlighn brings a rare blend of science and business acumen to HepaTx. His experience spans therapeutic classes including oncology, vaccines, immuno-oncology, and cardiovascular disease treatments and multiple aspects of drug development and commercialization. His accomplishments include: guided the discovery, evolution, and commercialization of Losartan (Cozaar®), a market-leading antihypertensive drug becoming a $3.5B franchise (Merck & Co.); co-led the development and commercialization of RotaTeq